Abstract:Background: Although use of inhaled bronchodilators in infants with acute bronchiolitis is not supported by evidence-based guidelines, it is often justified by the belief in a subgroup effect in individuals developing atopic disease. We aimed to assess if inhaled epinephrine during acute bronchiolitis in infancy would benefit patients with later recurrent bronchial obstruction, atopic eczema, or allergic sensitisation. Methods: In the randomised, double-blind, multicentre Bronchiolitis ALL trial, 404 infants with moderate-to-severe acute bronchiolitis were recruited from eight hospitals in Norway to receive either inhaled epinephrine or saline up to every second hour throughout the hospital stay. Randomisation was done centrally, and the two study medications (20 mg/mL racemic epinephrine or 0.9% saline) were prepared in identical bottles. The dose given depended on the infant's weight: 0.10 mL, less than 5 kg; 0.15 mL, 5-6.9 kg; 0.2 mL, 7-9.9 kg; and 0.25 mL, 10 kg or more; all dissolved in 2 mL of 0.9% saline before nebulisation. The primary outcome was the length of hospital stay. In this follow-up study, 294 children were reinvestigated at 2 years of age with an interview, a clinical examination, and a skin prick test for 17 allergens, determining bronchial obstruction, atopic eczema, and allergic sensitisation, on which subgroup analyses were done. Analyses were done by intention to treat. The trial has been completed and is registered at ClinicalTrials.gov (number NCT00817466) and EUDRACT (number 2009-012667-34). Findings: Length of stay did not differ between patients who received inhaled epinephrine versus saline in the subgroup of infants who developed recurrent bronchial obstruction by age 2 years (143 [48.6%] of 294 patients; p(interaction)=0.40). However, the presence of atopic eczema or allergic sensitisation by the age of 2 years (n=77) significantly interacted with the treatment effect of inhaled epinephrine (p(interaction)=0.02); the length of stay (mean 80.3 h, 95% CI 72.8-87.9) was significantly shorter in patients receiving inhaled epinephrine versus saline in patients without allergic sensitisation or atopic eczema by 2 years (-19.9 h, -33.1 to -6.3; p=0.003). No significant differences were found in length of hospital stay in response to epinephrine or saline in children with atopic eczema or allergic sensitisation by 2 years (+16.2 h, -11.0 to 43.3; p=0.24). Interpretation: Contrary to our hypothesis, hospital length of stay for bronchiolitis was not reduced by administration of inhaled epinephrine in infants who subsequently developed atopic eczema, allergic sensitisation, or recurrent bronchial obstruction. The present study does not support an individual trial of inhaled epinephrine in acute bronchiolitis in children with increased risk of allergic diseases. Funding: Medicines for Children Network, Norway.

Management of anaphylaxis after pre-hospital epinephrine use in children with food-induced anaphylaxis

Outcomes Associated with Prehospital Epinephrine in Adult and Pediatric Anaphylaxis Patients

Epinephrine autoinjectors for individuals with food allergy: Who, how many, and when to use

The Need for Required Stock Epinephrine in All Schools: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee

Anaphylaxis in Children: Epidemiology, Risk Factors and Management

Increased Use of Adrenaline in the Management of Childhood Anaphylaxis Over the Last Decade

Global disparities in availability of epinephrine auto-injectors

A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020)

Changes in epinephrine dispensings and allergy hospitalisations in Sweden in the years following the removal of autoinjector co-payments

Investigation of the underuse of adrenaline (epinephrine) and prognosis among patients with anaphylaxis at emergency department admission

Food anaphylaxis in schools: evaluation of the management plan and the efficiency of the emergency kit

Impact of Treatment on Rate of Biphasic Reaction in Children with Anaphylaxis

Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: an Analysis of the Beijing Pharmacovigilance Database

Fruit-Induced Anaphylaxis: Clinical Presentation and Management

A Health Economic Analysis of Non-injectable Epinephrine Compared with Intramuscular Epinephrine

Clinical Features and Treatment of Pediatric Patients with Drug-Induced Anaphylaxis: a Study Based on Pharmacovigilance Data

Anaphylaxis in children: Effect of age and atopic status

Evidence-based use of epinephrine in anaphylaxis

Teaching children with food allergy to recognize anaphylaxis: The caregivers' perspectives

Allergic diseases and the effect of inhaled epinephrine in children with acute bronchiolitis: follow-up from the randomised, controlled, double-blind, Bronchiolitis ALL trial

Management of Refractory Anaphylaxis: An Overview of Current Guidelines